1. Warlow C. The Willis Lecture 2003: evaluating treatments for stroke patients too slowly: time to get out of second gear. Stroke. 2004;35(9):2211–9.
2. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaurvedi S, et al. Anticoagulants and antiplatelet agents in acute ischaemic stroke. Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Neurology. 2002;59: 13–22.
3. West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF, et al. Systems to rate the strength of scientific evidence [Evidence report/technology assessment no 47]. Rockville (MD): Agency for Healthcare Research and Quality; 2002 Mar. AHRQ Publication No 02-E016.
4. Evaluation tools for COMPUS. The Canadian Agency for Drugs and Technologies in Health (Dec 2005). http://www.cadth.ca/media/compus/pdf/COMPUS_Evaluation_Methodology_final_e.pdf . Accessed 28 Feb 2009.
5. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118(15):e523–661. Epub 2008 Sep 26.